Vector Science & Therapeutics Announces Distributor Network Buildout to Support Its Peptide Portfolio Across Orthopedic, Sports, and Regenerative Medicine Channels
PR Newswire
MEQUON, Wis., July 21, 2026
Dedicated distributor force built for the orthopedic, sports, regenerative medicine, and pain management and rehabilitation (PMR) channels, supporting commercialization of Vector's peptide portfolio.National distribution channel planned, with initial launch efforts concentrated regionally and/or by clinical specialty to control rollout costs.Vector is advancing a development-stage peptide portfolio targeting unmet needs in musculoskeletal health, including applications in soft tissue recovery and joint health. All candidates are investigational and have not been approved for any indication.MEQUON, Wis., July 21, 2026 /PRNewswire/ -- Vector Science & Therapeutics Corp. (TSXV: PAIN) ("Vector" or the "Company") today announced plans to build a dedicated distributor network to support commercialization of its peptide portfolio across the orthopedic, sports, and regenerative medicine channels. The portfolio is focused on the clinical areas of musculoskeletal conditions, soft tissue injury, and degenerative joint disease, including osteoarthritis. The specialized force is designed to place the Company's peptide-based recovery offerings into the clinical settings where these conditions are managed.
